1 中山大学附属第六医院消化内科，广州 510655
Short-term efficacy and safety of vedolizumab in the treatment of inflammatory bowel disease: A single-center real-world study
CorrespondingAuthor: ZHI Min Email: firstname.lastname@example.org
Foundation: This work was supported by the National Natural Science Foundation of China (81900490, 81670477).
Objective: To figure out the short-term efficacy and safety of vedolizumab (VDZ) in the treatment of patients with inflammatory bowel disease (IBD). Methods: The clinical data of patients with IBD who received VDZ treatment in the Sixth Affiliated Hospital of Sun Yat-sen University from November 1st, 2020 to October 31st, 2021 were retrospectively studied, and their baseline data were collected. Crohn’s Disease Activity Index (CDAI) and Simple Endoscopic Score for Crohn’s Disease (SES-CD) were used to evaluate clinical and endoscopic severity in patients with Crohn’s disease (CD) while modified Mayo and Mayo endoscopic scores were used to evaluate clinical and endoscopic severity in patients with ulcerative colitis (UC), respectively. Meanwhile, the adverse effects of VDZ treatment were recorded. Results: A total of 39 patients with CD were included, 66.7% of which were male, with an age of (30.3±9.8) years and a disease duration of (80.1±57.7) months. C-reactive protein (CRP) [(12.8±10.0) mg/L vs (10.5±4.7) mg/L, P=0.03] and erythrocyte sedimentation rate (ESR) [(18.1±12.0) mm/h vs (13.0±3.8) mm/h, P<0.01) decreased while hemoglobin (HGb) [(129.6±20.8) g/L vs (122.3±23.4) g/L, P<0.01] and BMI [(20.2±3.3) kg/m2 vs (19.5±3.3) kg/m2, P<0.01] increased at week 22 after VDZ initiation. Clinical remission, clinical response, endoscopic remission, and endoscopic response rates for patients with CD were 71.4%, 87.2%, 29.4%, and 76.5%, respectively. A total of 13 patients with UC were included, 46.2% of which were male, with an age of (40.6±18.1) years and a disease duration of (101.8±105.2) months. ESR [(12.2±12.3) mm/h vs (28.8±26.4) mm/h, P<0.05) decreased while HGb [(118.2±16.5) g/L vs (107.4±19.1) g/L, P<0.05] increased at week 22 after VDZ initiation. Clinical remission, clinical response, endoscopic remission, and endoscopic response rates for patients with UC were 53.9%, 76.9%, 57.1%, and 57.1%, respectively. Adverse effect rate of VDZ treatment was 0.02% (1/56). Conclusion: VDZ can effectively induce and safely maintain remission of IBD.